Work

Abstract PS1-09-26: Phase II Trial of Anlotinib-Chemotherapy Combination in HER2-Negative Metastatic Breast Cancer: Therapeutic Efficacy and Proteomic Biomarker Profiling

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps1-09-26

Authors: Y. Yuan, T. Xu, Q. Gu, L. Zhang, S. Li

Institution: Nanjing Medical University

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129378965

Cites:

Cited by:

Related to: